Charles River Laboratories International, Inc. (CRL)
Creightons shares fall 10% as cautious outlook tempers improved results
Shares in Creightons PLC (LSE:CRL) dropped 10% on Wednesday despite reporting a return to profitability, as investors reacted to a cautious outlook for the year ahead. The beauty and personal care manufacturer posted a 1.6% rise in revenue to £54.1 million for the year to 31 March 2025, with strong growth in private label sales offsetting declines in branded and contract manufacturing.
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA
RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.
Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Charles River Stock May Gain From Extended CHDI Research Deal on HD
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
Should You Continue to Hold Charles River Stock in Your Portfolio?
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Understanding Charles River (CRL) Reliance on International Revenue
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Activist Elliott reaches key agreement with Charles River. Here are three ways to create value
The firm has three possible paths toward value creation at the drug development company.
S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments
The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.
Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL ) Q1 2025 Results Conference Call May 7, 2025 9:00 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Max Smock - William Blair Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Ann Hynes - Mizuho Securities Dave Windley - Jefferies Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank Kyle Crews - UBS Patrick Donnelly - Citi Casey Woodring - JPMorgan Charles Rhyee - TD Cowen Tejas Savant - Morgan Stanley Rob Cottrell - Cleveland Research Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories First Quarter 2025 Earnings Conference Call. This call is being recorded.
Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help.
The biotech said its largest investor would conduct a ‘strategic review' as revenue continued to decline.
Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More
U.S. equities were little changed at midday as the market awaited the Federal Reserve's interest-rate decision coming this afternoon. The Dow Jones Industrial Average was higher, the Nasdaq was lower, and the S&P 500 was basically flat.
Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
